What is Brainsgate?
Established in 2000, BrainsGate operates at the intersection of neurology and medical engineering. The company specializes in non-invasive or minimally invasive electrical stimulation of the SPG, a unique approach to mitigating the long-term disability associated with stroke and other CNS-related pathologies. By focusing on the physiological mechanisms of cerebral perfusion, BrainsGate has positioned itself as a high-authority player in the neuro-intervention market. Its platform technology is engineered to provide clinicians with a robust toolset for acute care, aiming to improve patient outcomes in environments where time-sensitive intervention is paramount.
How much funding has Brainsgate raised?
Brainsgate has raised a total of $40M across 2 funding rounds:
Unspecified
$26M
Private Equity
$14M
Unspecified (2015): $26M with participation from Elron Electronic Industries
Private Equity (2020): $14M led by BNP Paribas, Spero Health Inc, Agate Inc, Elron Electronic Industries Ltd., Pitango Venture Capital, Cipio, and Medtronic plc
Key Investors in Brainsgate
BNP Paribas
BNP Paribas is a leading international banking group providing comprehensive corporate and institutional banking services, including structured finance and capital markets support for global innovation projects.
Pitango Venture Capital
Pitango is a prominent venture capital firm that partners with visionary entrepreneurs, offering value-added support across its First, Growth, and HealthTech funds to foster long-term company maturity.
Elron Electronic Industries
Elron Electronic Industries is a foundational Israeli technology holding company with a deep history of funding and developing high-tech and medical technology enterprises since 1962.
What's next for Brainsgate?
With the infusion of capital from its most recent financing round, BrainsGate is well-positioned to accelerate its clinical development programs and expand its market reach. The strategic focus will likely shift toward securing regulatory milestones and scaling manufacturing capabilities to meet the demands of global healthcare systems. As the company matures, the integration of its SPG stimulation technology into standard stroke protocols remains a primary objective, potentially transforming the landscape of acute neurological care and establishing a new benchmark for therapeutic efficacy in the CNS sector.
See full Brainsgate company page
